D-1315-2020 Class III Terminated
FDA drug recall D-1315-2020 was initiated by Aurobindo Pharma USA Inc. on May 26, 2020 and is designated Class III. Reason for recall: Failed Impurities/ Degradation Specifications The recall status is terminated (terminated Jan 10, 2023). Affected quantity: 7547 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Jun 24, 2020
- Initiation Date
- May 26, 2020
- Termination Date
- Jan 10, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 7547 bottles
Product description
Olanzapine Tablets, USP 7.5 mg, 30-count bottle, Rx only, Manufactured for: Prasco Laboratories Mason, OH 45040 USA, Manufactured by: Aurolife Pharma LLC Dayton, NJ 08810, NDC 66993-682-30
Reason for recall
Failed Impurities/ Degradation Specifications
Distribution pattern
U.S.A. Nationwide
Code information
Lot #: 563180012A1, Exp 8/2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1315-2020
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026